RPS6KA1 and head and neck squamous cell carcinoma: Further, targeted inhibition of the downstream MAPK pathway member P90RSK, alone and in combination with alpelisib, resulted in a significant reduction in cell viability of alpelisib-resistant HNSCC cells, emphasizing the relevance of this pathway in circumventing PI3K inhibition.